[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l’INCa ».
Antineoplastic Agents
/ therapeutic use
Bevacizumab
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ diagnostic imaging
Chemotherapy, Adjuvant
Fallopian Tube Neoplasms
/ diagnostic imaging
Female
France
Humans
Hyperthermia, Induced
Lymph Node Excision
Magnetic Resonance Imaging
Ovarian Neoplasms
/ diagnostic imaging
Peritoneal Neoplasms
/ diagnostic imaging
Phthalazines
/ therapeutic use
Piperazines
/ therapeutic use
Societies, Medical
Ultrasonography
Cancer de la trompe
Cancer de l’ovaire
Cancer du péritoine primitif
Chemotherapy
Chimiothérapie
Chirurgie
Fallopian tube cancer
Guidelines
Ovarian cancer
Peritoneal cancer
Recommandations
Surgery
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
06
01
2019
accepted:
18
01
2019
pubmed:
10
3
2019
medline:
19
4
2019
entrez:
10
3
2019
Statut:
ppublish
Résumé
Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).
Identifiants
pubmed: 30850152
pii: S0007-4551(19)30091-8
doi: 10.1016/j.bulcan.2019.01.014
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Phthalazines
0
Piperazines
0
Bevacizumab
2S9ZZM9Q9V
olaparib
WOH1JD9AR8
Types de publication
Journal Article
Practice Guideline
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
354-370Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.